NewsBenzingaRevolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Revolution Medicines Begins Treating Patients In RASolute 309, Global, Randomized Phase 3 Clinical Trial Evaluating Combination Of RASONQUE And Zoldonrasib As First-Line Treatment In Adult Patients With Metastatic RAS G12D PDAC Benzinga 2026.10.05 12:02 (GMT+0) Open on Benzinga Other news Jones Trading Maintains Buy on Dynex Cap, Lowers Price Target to $12.5 Here's How Much $100 Invested In Gartner 20 Years Ago Would Be Worth Today Microsoft says AI agents are like insider threats as ‘frontier models can’t be trusted’ Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals Here's How Much $100 Invested In Fastenal 10 Years Ago Would Be Worth Today Bernstein Just Upgraded Datadog Stock. Here's Why.
Dorchester Minerals Enters Into An Agreement To Acquire Mineral And Royalty Interests; To Buy ~ 4,300 Net Royalty Acres In Williston Basin, North Dakota; Interests To Be Exchanged For 1,250,000 Common Units Of Dorchester Minerals
